Aclaris Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2016 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Aclaris Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2016 to Q3 2024.
  • Aclaris Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 27 %, a 15.9% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 27 -5.11 -15.9% Sep 30, 2024
Q2 2024 27.4 -0.18 -0.65% Jun 30, 2024
Q1 2024 29.9 +5.86 +24.3% Mar 31, 2024
Q4 2023 31.5 +8.3 +35.8% Dec 31, 2023
Q3 2023 32.1 +9.23 +40.4% Sep 30, 2023
Q2 2023 27.6 +4.78 +21% Jun 30, 2023
Q1 2023 24.1 -0.24 -0.99% Mar 31, 2023
Q4 2022 23.2 -3.66 -13.6% Dec 31, 2022
Q3 2022 22.8 -7.72 -25.3% Sep 30, 2022
Q2 2022 22.8 -16.7 -42.2% Jun 30, 2022
Q1 2022 24.3 -37.8 -60.8% Mar 31, 2022
Q4 2021 26.9 -47.7 -64% Dec 31, 2021
Q3 2021 30.6 -30.8 -50.2% Sep 30, 2021
Q2 2021 39.5 -28.2 -41.7% Jun 30, 2021
Q1 2021 62.1 -1.3 -2.05% Mar 31, 2021
Q4 2020 74.5 +20.9 +39% Dec 31, 2020
Q3 2020 61.3 +15.1 +32.7% Sep 30, 2020
Q2 2020 67.7 +32.3 +91% Jun 30, 2020
Q1 2020 63.4 +37.1 +141% Mar 31, 2020
Q4 2019 53.6 +34.9 +186% Dec 31, 2019
Q3 2019 46.2 +33.4 +260% Sep 30, 2019
Q2 2019 35.4 +25.6 +260% Jun 30, 2019
Q1 2019 26.3 +18.6 +243% Mar 31, 2019
Q4 2018 18.8 +12.5 +199% Dec 31, 2018
Q3 2018 12.9 +7.68 +149% Sep 30, 2018
Q2 2018 9.85 +5.34 +118% Jun 30, 2018
Q1 2018 7.66 +3.01 +64.7% Mar 31, 2018
Q4 2017 6.26 +1.2 +23.7% Dec 31, 2017
Q3 2017 5.16 +0.43 +9.09% Sep 30, 2017
Q2 2017 4.51 -1.35 -23% Jun 30, 2017
Q1 2017 4.65 Mar 31, 2017
Q4 2016 5.06 Dec 31, 2016
Q3 2016 4.73 Sep 30, 2016
Q2 2016 5.87 Jun 30, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.